Douglas D. Fang

1.5k citations

33 papers · 632 indexed · h-index 12

Co-authors: Yifan Zhai Dajun Yang Qixin Wang Qiuqiong Tang James G. Christensen Maruja E. LiraFang XuJohn T. Norton
Topics: Cancer-related Molecular Pathways (9 papers)Cancer Cells and Metastasis (7 papers)Chronic Lymphocytic Leukemia Research (5 papers)
Cited by: Oncology Cancer Research Molecular Biology
Journals: PLoS ONE Cancer Research Oncogene
Partner nations: China United States Germany

In The Last Decade

Douglas D. Fang

29 papers receiving 624 citations

Peers

Countries citing papers authored by Douglas D. Fang

Since Specialization

Citations

This map shows the geographic impact of Douglas D. Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas D. Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas D. Fang more than expected).

Fields of papers citing papers by Douglas D. Fang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas D. Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas D. Fang. The network helps show where Douglas D. Fang may publish in the future.

Co-authorship network of co-authors of Douglas D. Fang

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas D. Fang. A scholar is included among the top collaborators of Douglas D. Fang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas D. Fang. Douglas D. Fang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies 2022 ·Clinical Cancer Research ·Yifan Zhai,(unknown),Douglas D. Fang,Jing Deng,(unknown),(unknown),(unknown),Chengcheng Fu,Shengli Xue,(unknown),(unknown),Dajun Yang	10
2	Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models 2022 ·BMC Cancer ·Douglas D. Fang,Ran Tao,Guangfeng Wang,(unknown),Kaixiang Zhang,(unknown),(unknown),Qixin Wang,Jingwen Wang,Chunyan Tang,(unknown),(unknown),Jianyong Chen,Shaomeng Wang,Dajun Yang,Yifan Zhai	22
3	Abstract 2664: Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors 2022 ·Cancer Research ·(unknown),Qiang Li,Chao Li,Qixin Wang,Douglas D. Fang,Shaomeng Wang,Dajun Yang,Yifan Zhai	1
4	Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations 2022 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Lu Zhang,(unknown),Zhenzhen Zhu,Jing Jin,Yuxin Qin,(unknown),(unknown),Douglas D. Fang,Wen Jiang,Lihong Hu,Jinhua Chen,Kevin Chen,Shu‐Hui Chen,Jian Li,(unknown),(unknown),Long Zhang,Charles Z. Ding	8
5	FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia 2021 ·Translational Oncology ·Douglas D. Fang,Hengrui Zhu,Qiuqiong Tang,Guangfeng Wang,(unknown),Qixin Wang,Na Li,Dajun Yang,Yifan Zhai	16
6	MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models 2021 ·Cell Death Discovery ·Douglas D. Fang,Qiuqiong Tang,(unknown),Rong Tao,Qixin Wang,Na Li,F. Xu,(unknown),(unknown),Yan Yin,Jing Deng,Dajun Yang,Yifan Zhai	39
7	Abstract 4217: Synergy of tyrosine kinase inhibitor HQP1351 and MDM2-P53 antagonist, APG-115, in preclinical models of FLT3 mutant and TP53 wild-type acute myeloid leukemia 2020 ·Cancer Research ·Douglas D. Fang,Qiuqiong Tang,Qixin Wang,Na Li,(unknown),(unknown),(unknown),Rong Tao,Guangfeng Wang,Dajun Yang,Yifan Zhai	2
8	Abstract 73: Development of APG-3526 as a novel and highly efficacious MCL-1 inhibitor 2020 ·Cancer Research ·Jianyong Chen,(unknown),(unknown),Leilei Zhao,Yunlong Zhou,Dongbo Li,Guozhi Tang,(unknown),Jing Deng,Guangfeng Wang,Douglas D. Fang,Shaomeng Wang,Dajun Yang,Yifan Zhai	2
9	Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors 2019 ·Cell & Bioscience ·Xuechao Liu,Guangfeng Wang,Xianglei Yan,Haibo Qiu,(unknown),(unknown),(unknown),Fei Zhang,Qiuqiong Tang,Saijie Zhu,Miao‐Zhen Qiu,Wei Zhuang,Douglas D. Fang,Zhiwei Zhou,Dajun Yang,Yifan Zhai	16
10	MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment 2019 ·Journal for ImmunoTherapy of Cancer ·Douglas D. Fang,Qiuqiong Tang,(unknown),Qixin Wang,(unknown),Fang Xu,Peng Zou,Rong Tao,Jingwen Wang,Dajun Yang,Yifan Zhai	118
11	Abstract 3192: Activation of p53 in the tumor microenvironment by MDM2 inhibitor APG-115 synergizes with PD-1 blockade independently of p53 status of tumor cells 2019 ·Cancer Research ·Douglas D. Fang,Qiuqiong Tang,(unknown),Qixin Wang,(unknown),Fang Xu,Peng Zou,Rong Tao,Jingwen Wang,Dajun Yang,Yifan Zhai	1
12	Abstract 1979: HQP1351, a novel multikinase inhibitor in clinical development, overcomes drug resistance for the treatment of gastrointestinal stromal tumors in preclinical models 2018 ·Cancer Research ·Guangfeng Wang,Haibo Qiu,(unknown),(unknown),(unknown),(unknown),Fei Zhang,Wei Zhuang,Zhiwei Zhou,Douglas D. Fang,Dajun Yang,Yifan Zhai	1
13	HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib 2014 ·Journal of Thoracic Oncology ·Douglas D. Fang,Bin Zhang,Qingyang Gu,Maruja E. Lira,Qiang Xu,Hongye Sun,Maoxiang Qian,Weiqi Sheng,Mark Ozeck,Zhenxiong Wang,Cathy Zhang,Xinsheng Chen,(unknown),Jian Li,Shu‐Hui Chen,James G. Christensen,Mao Mao,Chi-Chung Chan	74
14	Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation 2013 ·PLoS ONE ·Douglas D. Fang,Cathy C. Zhang,Yin Gu,Jitesh P. Jani,Joan Cao,Konstantinos Tsaparikos,Jing Yuan,(unknown),Amy Jackson-Fisher,(unknown),Patrick B. Lappin,Tomoko Hayashi,Richard B. Schwab,Anthony Wong,(unknown),Shubha Bagrodia,(unknown),Steve Bender,James G. Christensen,Todd VanArsdale	33
15	Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line 2013 ·Frontiers of Medicine ·Douglas D. Fang,Joan Cao,Jitesh P. Jani,Konstantinos Tsaparikos,Alessandra Blasina,(unknown),Maruja E. Lira,Jian-Ying Wang,(unknown),(unknown),Zhou Zhu,Yin Gu,Gerrit Los,Zdeněk Hostomský,Todd VanArsdale	15
16	Synergistic Effect of the γ-Secretase Inhibitor PF-03084014 and Docetaxel in Breast Cancer Models 2013 ·Stem Cells Translational Medicine ·Cathy C. Zhang,Zhengming Yan,(unknown),Douglas D. Fang,Cory L. Painter,Qin Zhang,Enhong Chen,Maruja E. Lira,(unknown),James G. Christensen	78
17	Identification of cancer stem cells provides novel tumor models for drug discovery 2012 ·Frontiers of Medicine ·Douglas D. Fang,Danyi Wen,Yajun Xu	2
18	Abstract LB-397: Deep sequencing of Xenografts and case-matched blood and primary tumors reveals a 20 folds enrichment of loss of heterozygosity versus somatic mutations suggesting LOH plays an ever important role in tumorigenesis 2012 ·Cancer Research ·Qiang Xu,Guan Wang,Douglas D. Fang,Yibo Gao,(unknown),Lele Sun,(unknown),Li Ou,(unknown),Maoxiang Qian,Bin Zhang,Zhaoli Chen,Chi-Chung Chan,Hongye Sun,Jie He	1
19	Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery 2010 ·British Journal of Cancer ·Douglas D. Fang,(unknown),(unknown),Sita Aggarwal,Katherine McKinnon,(unknown),John T. Norton,Charles E. Birse,Tao He,Steven M. Ruben,Paul A. Moore	120
20	Abstract 4483: Establishing patient-derived colorectal cancer stem cell models with a PIK3CA mutation for the development of inhibitory drugs as targeted therapies 2010 ·Cancer Research ·Douglas D. Fang,Yin Gu,Konstantinos Tsaparikos,(unknown),Amy Jackson-Fisher,Joan Cao,(unknown),(unknown),Jitesh P. Jani,Tomoko Hayashi,Richard B. Schwab,Anthony Wong,(unknown),Patrick B. Lappin,Hengmiao Cheng,Steve Bender,Shubha Bagrodia,Min-Jean Yin,Todd VanArsdale	1

About Douglas D. Fang

Douglas D. Fang is a scholar working on Oncology, Genetics and Hematology, having authored 33 papers that have together received 632 indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (9 papers), Cancer Cells and Metastasis (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Oncology (408 citations), Cancer Research (146 citations) and Molecular Biology (333 citations). Douglas D. Fang has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Yifan Zhai, Dajun Yang, Qixin Wang, Qiuqiong Tang, James G. Christensen, Maruja E. Lira, Fang Xu, John T. Norton, Tao He and Rong Tao. Their work appears in journals such as PLoS ONE, Cancer Research and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact